Approach to the patient with prediabetes.
Prediabetes consists of impaired fasting glucose and/or impaired glucose tolerance and is a significant risk factor for the development of type 2 diabetes, microvascular, and macrovascular disease. The values used to define prediabetes are arbitrary, because prediabetes represents an intermediary category along the continuum from normal glucose levels and tolerance to overt hyperglycemia. The progression from prediabetes to type 2 diabetes occurs over many years, strong evidence to support intervention to delay the progression from prediabetes to diabetes. Large, randomized prospective studies with lifestyle intervention and/or various modes of pharmacotherapy have demonstrated successful delay of diabetes. Several issues in the management of prediabetes remain controversial, such as the role of pharmacotherapy and when to escalate treatment. This article will review some of the issues surrounding the identification and treatment of prediabetes, with an interpretation of the available data to help guide management.
Aroda
Vanita R
VR
Med Star Clinical Research Center, 650 Pennsylvania Avenue SE, Washington, DC 20003, USA.
Ratner
Robert
R
D003924:Diabetes Mellitus, Type 2 / Q000517:prevention & control; D018450:Disease Progression; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D008687:Metformin / Q000627:therapeutic use; D011236:Prediabetic State / Q000175:diagnosis* / Q000628:therapy*; D040242:Risk Reduction Behavior; D013997:Time Factors
D007004:Hypoglycemic Agents; D008687:Metformin